Indivior Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: INDVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Indivior Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Indivior Pharmaceuticals generated $229.0 million of operating cash flow and spent $7.0 million on capital expenditures. That left free cash flow of $222.0 million, a free-cash-flow margin of 64.7% of revenue. Free cash flow was up 57.4% from the prior year's $141.0 million.
Indivior Pharmaceuticals returned $177.0 million to shareholders through share repurchases, equal to 80% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Indivior Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 122.00M | 89.00M | 102.00M | 42.00M | 18.00M | 47.00M | 21.00M | 22.00M | -97.00M | 61.00M |
| Net Income growth (YoY) | +577.78% | +89.36% | +385.71% | +90.91% | — | -22.95% | — | — | — | — |
| Depreciation & Amortization | 2.00M | 2.00M | 2.00M | 3.00M | 2.00M | 3.00M | 5.00M | 4.00M | 2.00M | 5.00M |
| Stock-Based Compensation | 11.00M | 9.00M | 5.00M | 7.00M | 8.00M | 6.00M | 6.00M | 6.00M | 6.00M | 6.00M |
| Change in Working Capital | 63.00M | -125.00M | 11.00M | -99.00M | 120.00M | 79.00M | -81.00M | 9.00M | 40.00M | 373.00M |
| Operating Cash Flow | 229.00M | -9.00M | -221.00M | -39.00M | 158.00M | 75.00M | -17.00M | 2.00M | 88.00M | -37.00M |
| Capital Expenditures | -7.00M | -20.00M | -24.00M | -20.00M | -17.00M | -5.00M | -16.00M | -7.00M | -4.00M | -2.00M |
| Investing Cash Flow | -8.00M | -19.00M | -24.00M | -20.00M | -17.00M | -5.00M | 8.00M | 35.00M | 1.00M | 25.00M |
| Share Repurchases | -177.00M | -125.00M | 0 | 0 | 0 | -11.00M | -50.00M | -52.00M | -35.00M | -36.00M |
| Debt Issued | 0 | 489.00M | — | — | 0 | 0 | — | — | — | — |
| Debt Repaid | 0 | -333.00M | -5.00M | -4.00M | -4.00M | -4.00M | -238.00M | -1.00M | 0 | -1.00M |
| Financing Cash Flow | -173.00M | 7.00M | -5.00M | -3.00M | -5.00M | -17.00M | 40.00M | -51.00M | -35.00M | -56.00M |
| Net Change in Cash | 48.00M | -20.00M | -252.00M | -61.00M | 136.00M | 53.00M | 31.00M | -14.00M | — | -68.00M |
| Free Cash Flow | 222.00M | -29.00M | -245.00M | -59.00M | 141.00M | 70.00M | -33.00M | -5.00M | 84.00M | -39.00M |
This table shows 10 quarterly periods of Indivior Pharmaceuticals's cash flow statement, from Q2 2026 back to Q1 2024, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow INDV's reporting calendar. What is a cash flow statement?